drugset / Trial / NCT07199413
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.
Timeline
- Start
- 2026-06-15
- Primary completion
- 2029-04-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg/m2 | Intravenous |
| Subject | SV-BR-1-GM | Vaccine | 2e+07 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | interferon alfa-2b | Protein / enzyme biologic | 0.18 ug | Subcutaneous |